BUROSUMAB
Slovakia · Košice - mestská časť Západ · how to bid here →
Your path to submission
- Deadline: 23 October at 09:00 — 20 days left.
- The submission point is stated in the notice (link on the right).
- Offer and evidence in: SLK.
- Collect your evidence — the eligibility requirements are listed above; for many of them the analysis explains how to obtain them.
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every 4 months (25 awards, most recently September 2026) — the next award is due around January 2027 by that rhythm. The last award went to PHOENIX Zdravotnícke zásobovanie, a.s..n = 25
- 35% of this buyer's awards went to companies that had already won here before (44 awards since 2019, spread over 18 companies). That is well below the sector norm (63%) — this buyer switches suppliers more often than others.n = 44 awards since 2019
- 42% of the bids received came from small and medium-sized enterprises (34 procedures with a bid mix). Sector: 72%.n = 34
- The median procedure drew 2 bids (43 procedures with a bid count); 23% ended with a single bidder. Sector: median 2 bids.n = 43
- The award came in at a median 94% of the estimated value (11 awards with both estimate and value) — pricing at the estimate is usually too high here. Sector: 91%.n = 11
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 27/09/2026.
Foreign bidders
In Slovakia · Medical equipment & pharma, 17 contracts went to foreign companies over the last 3 years (of 1,850 recorded awards).
Submission language: SLK.
Typical field: median 2 (from 25 awards).
What the buyer is looking for
The subject of the contract is the supply of a medicinal product: burosumab 20mg solution for injection and burosumab 30 mg solution for injection with the active substance burosumab, known as Crysvita (‘the product’), for paediatric patients with X-linked hypophosphatemic rickets meeting all of the criteria listed below: 1) with documented high serum concentration of FGF-23 2) with genetically confirmed mutation in PHEX gene 3) persistence of low hypophosphataemia despite long-term substitution by maximum tolerated doses of phosphate solution and active form of vitamin D 4) in progression of bone deformities despite administration of maximum tolerated doses of standard therapy (phosphates and vitamin D).
Selection criteria — in the procurement documents
The buyer states in the notice that the selection criteria are in the procurement documents (link on the right), not in the EU form. The document analysis below extracts them from there — bid and evidence in Slovak.
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| MED - ART, spol. s r.o. | 9 | 2024–2025 |
| PHOENIX Zdravotnícke zásobovanie, a.s. | 4 | 2024–2026 |
| Stargen EU s.r.o. | 3 | 2025 |
| Up Déjeuner, s. r. o. | 2 | 2024–2026 |
| AGB ekoservis s.r.o. | 2 | 2025 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.